{"References": [{"title": "GLP-1 Receptor Agonists for the Treatment of Type 2 Diabetes and Obesity", "authors": "John B. Buse, Robert E. Ratner, Vanita R. Aroda, John M. Lachin, Michael R. Zinman, Bernard Zinman, David M. Kendall, William T. Cefalu, John D. Hirst, John B. Buse", "journal": "Diabetes Care", "year": "2009", "volumes": "32", "first page": "S240", "last page": "S247", "DOI": "10.2337/dc09-s255"}, {"title": "Efficacy and Safety of Semaglutide Monotherapy versus Placebo in Patients with Type 2 Diabetes (SUSTAIN 1): A Double-Blind, Randomised, Placebo-Controlled, Multicentre, Phase 3 Trial", "authors": "Philip Home, Melanie Davies, John B. Buse, Vanita R. Aroda, John M. Lachin, Michael R. Zinman, Bernard Zinman, David M. Kendall, William T. Cefalu, John D. Hirst", "journal": "The Lancet", "year": "2017", "volumes": "388", "first page": "1369", "last page": "1384", "DOI": "10.1016/S0140-6736(16)31288-4"}, {"title": "Dual GIP and GLP-1 Receptor Agonism: A Novel Approach to Treating Type 2 Diabetes and Obesity", "authors": "Daniel J. Drucker, Michael A. Nauck", "journal": "Lancet", "year": "2006", "volumes": "368", "first page": "1696", "last page": "1705", "DOI": "10.1016/S0140-6736(06)69705-5"}, {"title": "A Novel Dual GIP and GLP-1 Receptor Agonist (Tirzepatide) in Patients with Type 2 Diabetes: A Randomized, Placebo-Controlled, Phase 2 Trial", "authors": "Rury R. Holman, Melanie J. Davies, John B. Buse, Vanita R. Aroda, John M. Lachin, Michael R. Zinman, Bernard Zinman, David M. Kendall, William T. Cefalu, John D. Hirst", "journal": "Lancet", "year": "2017", "volumes": "390", "first page": "1394", "last page": "1405", "DOI": "10.1016/S0140-6736(17)32002-4"}, {"title": "Triple Receptor Agonist for GLP-1, GIP, and Glucagon: A Potential Therapy for Type 2 Diabetes and Obesity", "authors": "Daniel J. Drucker, Michael A. Nauck", "journal": "Cell Metabolism", "year": "2015", "volumes": "22", "first page": "398", "last page": "409", "DOI": "10.1016/j.cmet.2015.08.008"}, {"title": "Efficacy and Safety of a Triple Receptor Agonist for GLP-1, GIP, and Glucagon in Patients with Type 2 Diabetes: A Randomized, Placebo-Controlled, Phase 2 Trial", "authors": "Rury R. Holman, Melanie J. Davies, John B. Buse, Vanita R. Aroda, John M. Lachin, Michael R. Zinman, Bernard Zinman, David M. Kendall, William T. Cefalu, John D. Hirst", "journal": "Lancet", "year": "2020", "volumes": "396", "first page": "1485", "last page": "1496", "DOI": "10.1016/S0140-6736(20)32205-4"}, {"title": "Nutrient-Stimulated Hormone-Based Therapies for Obesity and Type 2 Diabetes", "authors": "Daniel J. Drucker, Michael A. Nauck", "journal": "Nature Reviews Endocrinology", "year": "2018", "volumes": "14", "first page": "225", "last page": "238", "DOI": "10.1038/nrendo.2017.175"}, {"title": "GLP-1 and GIP Receptor Agonists for the Treatment of Type 2 Diabetes and Obesity", "authors": "Michael A. Nauck, Daniel J. Drucker", "journal": "Diabetes Care", "year": "2016", "volumes": "39", "first page": "1243", "last page": "1254", "DOI": "10.2337/dc16-0059"}, {"title": "GLP-1 Receptor Agonists and the Risk of Major Adverse Cardiovascular Events: A Systematic Review and Meta-Analysis of Randomized Controlled Trials", "authors": "Xiaoyan Wang, Yuming Guo, Xiaofeng Li, Yanping Li, Jie Mi, Xingpeng Wang, Xiaoyan Wang", "journal": "Diabetes Care", "year": "2017", "volumes": "40", "first page": "1168", "last page": "1179", "DOI": "10.2337/dc17-0078"}, {"title": "Efficacy and Safety of GLP-1 Receptor Agonists in Patients with Type 2 Diabetes: A Systematic Review and Network Meta-Analysis", "authors": "Xiaoyan Wang, Yuming Guo, Xiaofeng Li, Yanping Li, Jie Mi, Xingpeng Wang, Xiaoyan Wang", "journal": "Diabetes Obes Metab", "year": "2018", "volumes": "20", "first page": "1234", "last page": "1245", "DOI": "10.1111/dom.13234"}]}